Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Phase 2

• Conditions: Central Serous Chorioretinopathy; Pars Planitis; Cystoid Macular Edema; Irvine-Gass Syndrome
• Interventions: Drug: Triamcinolone Acetonide

• Registration Number: NCT05337332
• Lead Sponsor: Benha University

Brief Summary

Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

Detailed Description

Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.

Study Timeline

• Status Verified: 2022-04
• Study First Submitted: 2022-04-13
• Study First Submitted QC: 2022-04-13
• Last Update Submitted: 2022-04-13
• Study Start: 2022-04-14
• Study First Posted: 2022-04-20
• Last Update Posted: 2022-04-20
• Primary Completion: 2023-05-30
• Study Completion: 2023-06-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery.

Exclusion Criteria

• other retinal diseases that may affect CMT and final visual outcome.
• Patients with dense corneal opacity.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Central serous chorioretinopathy group	Triamcinolone Acetonide	Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.
Irvine-Gass Syndrome group	Triamcinolone Acetonide	Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide

Primary Outcome Measures

Name	Time	Method
Central macular thickness	Baseline and 12 months after injection.	Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT)

Secondary Outcome Measures

Name	Time	Method
Best corrected visual acuity	Baseline and 12 months after injection.	Changes in best corrected visual acuity (BCVA) measured in logarithm of minimal angle of resolution (LogMAR) by chart projector.

Trial Locations

Locations (1)

Ahmed Abdelshafy; 🇪🇬 Banhā, QA, Egypt